{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:42Z","timestamp":1790983182779,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.7759\/cureus.111913","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:02:44Z","timestamp":1782932564000},"source":"Crossref","is-referenced-by-count":1,"title":["Effective Multi-agent Therapy With Anakinra, Corticosteroids and Mycophenolate in Immunotherapy-Associated Haemophagocytic Lymphohistiocytosis (HLH)"],"prefix":"10.7759","author":[{"given":"Anirban Deb","family":"Tanmoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan Jiong","family":"Eaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mykura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanush Sheeba","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12293","article-title":"Advances in understanding the pathogenesis of HLH","volume":"161","author":"Usmani GN","year":"2013","unstructured":"Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013, 161:609-22. 10.1111\/bjh.12293","journal-title":"Br J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/107327481402100406","article-title":"Hereditary and acquired hemophagocytic lymphohistiocytosis","volume":"21","author":"Zhang L","year":"2014","unstructured":"Zhang L, Zhou J, Sokol L. Hereditary and acquired hemophagocytic lymphohistiocytosis. Cancer Control. 2014, 21:301-12. 10.1177\/107327481402100406","journal-title":"Cancer Control"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin J","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019, 381:1535-46. 10.1056\/NEJMoa1910836","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2024.102896","article-title":"Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: a review of the current knowledge and future directions","volume":"110","author":"Walmsley CS","year":"2025","unstructured":"Walmsley CS, Schoepflin Z, De Brabandt C, Rangachari D, Berwick S, Patell R. Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: a review of the current knowledge and future directions. Blood Cells Mol Dis. 2025, 110:102896. 10.1016\/j.bcmd.2024.102896","journal-title":"Blood Cells Mol Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.04.034","article-title":"Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients","volume":"127","author":"Rivi\u00e8re S","year":"2014","unstructured":"Rivi\u00e8re S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, Fardet L. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014, 127:1118-25. 10.1016\/j.amjmed.2014.04.034","journal-title":"Am J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1960","article-title":"Hemophagocytic lymphohistiocytosis induced by nivolumab\/ipilimumab combination therapy: a case of lung adenocarcinoma that responded to early steroid pulse therapy","volume":"7","author":"Hagiwara S","year":"2024","unstructured":"Hagiwara S, Tanizaki J, Hayashi H, et al.. Hemophagocytic lymphohistiocytosis induced by nivolumab\/ipilimumab combination therapy: a case of lung adenocarcinoma that responded to early steroid pulse therapy. Cancer Rep (Hoboken). 2024, 7:e1960. 10.1002\/cnr2.1960","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/crom\/5582848","article-title":"Hemophagocytic lymphohistiocytosis (HLH) following immune checkpoint therapy (ICT)","volume":"2025","author":"Gajagowni S","year":"2025","unstructured":"Gajagowni S, Wang E, Wang J, Campbell MT, Siddiqui BA. Hemophagocytic lymphohistiocytosis (HLH) following immune checkpoint therapy (ICT). Case Rep Oncol Med. 2025, 2025:5582848. 10.1155\/crom\/5582848","journal-title":"Case Rep Oncol Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e P","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, et al.. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019, 133:2465-77. 10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.127","article-title":"Hemophagocytic lymphohistiocytosis (HLH) and related disorders","volume":"2009","author":"Filipovich AH","year":"2009","unstructured":"Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009, 2009:127-31. 10.1182\/asheducation-2009.1.127","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref10","unstructured":"Getting It Right First Time (GIRFT). Haemophagocytic Lymphohistiocytosis (HLH). Guidance on the diagnosis, treatment, management and governance. (2024). Accessed. April 2026: https:\/\/gettingitrightfirsttime.co.uk\/wp-content\/uploads\/2026\/04\/HLH-Guide-UPDATED-April-2026.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily EM","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, et al.. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020, 72:326-34. 10.1002\/art.41103","journal-title":"Arthritis Rheumatol"},{"key":"ref12","article-title":"Anakinra","year":"2020","unstructured":"Anakinra. LiverTox\u00ae. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2020."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa750","article-title":"First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors","volume":"60","author":"Azari AE","year":"2021","unstructured":"Azari AE, Stratton R, Singh A. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors. Rheumatology (Oxford). 2021, 60:e167-8. 10.1093\/rheumatology\/keaa750","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034898","article-title":"Outcome of patients with primary and secondary hemophagocytic lymphohistiocytosis: a retrospective analysis from a tertiary care center","volume":"102","author":"Abbasi AM","year":"2023","unstructured":"Abbasi AM, Shaikh MU, Shariq M, Arif MS, Arshad A, Raheem A, Ali N. Outcome of patients with primary and secondary hemophagocytic lymphohistiocytosis: a retrospective analysis from a tertiary care center. Medicine (Baltimore). 2023, 102:e34898. 10.1097\/MD.0000000000034898","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2340144","article-title":"Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases","volume":"29","author":"Xu Z","year":"2024","unstructured":"Xu Z, Li H, Yu X, Luo J, Zhang Z. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases. Hematology. 2024, 29:10.1080\/16078454.2024.2340144","journal-title":"Hematology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1464","article-title":"Hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitor therapy","volume":"13","author":"Rajapakse P","year":"2022","unstructured":"Rajapakse P, Andanamala H. Hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitor therapy. World J Oncol. 2022, 13:49-52. 10.14740\/wjon1464","journal-title":"World J Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment","volume":"58","author":"Carter SJ","year":"2019","unstructured":"Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019, 58:5-17. 10.1093\/rheumatology\/key006","journal-title":"Rheumatology (Oxford)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195799","article-title":"Anakinra for the treatment of hemophagocytic lymphohistiocytosis: 21 cases","volume":"11","author":"Baverez C","year":"2022","unstructured":"Baverez C, Grall M, Gerfaud-Valentin M, et al.. Anakinra for the treatment of hemophagocytic lymphohistiocytosis: 21 cases. J Clin Med. 2022, 11:5799. 10.3390\/jcm11195799","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14029","article-title":"Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review","volume":"111","author":"Charlesworth JE","year":"2023","unstructured":"Charlesworth JE, Kavirayani A. Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review. Eur J Haematol. 2023, 111:458-76. 10.1111\/ejh.14029","journal-title":"Eur J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives","volume":"13","author":"Liu Z","year":"2022","unstructured":"Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol. 2022, 13:1077468. 10.3389\/fphar.2022.1077468","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-024-01686-3","article-title":"Combined immunosuppression with cyclosporin A, mycophenolate mofetil (MMF) and dexamethasone for activity control of recurrent secondary hemophagocytic lymphohistiocytosis (sHLH) with underlying systemic lupus erythematosus (SLE) [Article in German]","volume":"65","author":"Saleh M","year":"2024","unstructured":"Saleh M, Hampel K, Gerth J, Merkelbach S, Monecke A, M\u00fcgge LO. Combined immunosuppression with cyclosporin A, mycophenolate mofetil (MMF) and dexamethasone for activity control of recurrent secondary hemophagocytic lymphohistiocytosis (sHLH) with underlying systemic lupus erythematosus (SLE) [Article in German]. Inn Med (Heidelb). 2024, 65:843-9. 10.1007\/s00108-024-01686-3","journal-title":"Inn Med (Heidelb)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500021-effective-multi-agent-therapy-with-anakinra-corticosteroids-and-mycophenolate-in-immunotherapy-associated-haemophagocytic-lymphohistiocytosis-hlh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:02:51Z","timestamp":1782932571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500021-effective-multi-agent-therapy-with-anakinra-corticosteroids-and-mycophenolate-in-immunotherapy-associated-haemophagocytic-lymphohistiocytosis-hlh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.111913","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}